Format

Send to

Choose Destination
See comment in PubMed Commons below
Circ Res. 2014 Apr 11;114(8):1281-91. doi: 10.1161/CIRCRESAHA.114.301475. Epub 2014 Mar 5.

Nitrite therapy improves left ventricular function during heart failure via restoration of nitric oxide-mediated cytoprotective signaling.

Author information

1
From the LSU Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA (S.B., D.J.P., H.O., D.J.L.); Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (K.K., T.M.); Division of Cardiothoracic Surgery, Department of Surgery, Carlyle Fraser Heart Center (C.K.N., J.W.C.) and Division of Cardiology, Department of Medicine (V.V.G., J.B.), Emory University School of Medicine, Atlanta, GA; and Department of Anatomy, Physiology, and Pharmacology, Auburn University College of Veterinary Medicine, AL (Y.-X.T., H.H.).

Abstract

RATIONALE:

Nitric oxide (NO) bioavailability is reduced in the setting of heart failure. Nitrite (NO2) is a critically important NO intermediate that is metabolized to NO during pathological states. We have previously demonstrated that sodium nitrite ameliorates acute myocardial ischemia/reperfusion injury.

OBJECTIVE:

No evidence exists as to whether increasing NO bioavailability via nitrite therapy attenuates heart failure severity after pressure-overload-induced hypertrophy.

METHODS AND RESULTS:

Serum from patients with heart failure exhibited significantly decreased nitrosothiol and cGMP levels. Transverse aortic constriction was performed in mice at 10 to 12 weeks. Sodium nitrite (50 mg/L) or saline vehicle was administered daily in the drinking water postoperative from day 1 for 9 weeks. Echocardiography was performed at baseline and at 1, 3, 6, and 9 weeks after transverse aortic constriction to assess left ventricular dimensions and ejection fraction. We observed increased cardiac nitrite, nitrosothiol, and cGMP levels in mice treated with nitrite. Sodium nitrite preserved left ventricular ejection fraction and improved left ventricular dimensions at 9 weeks (P<0.001 versus vehicle). In addition, circulating and cardiac brain natriuretic peptide levels were attenuated in mice receiving nitrite (P<0.05 versus vehicle). Western blot analyses revealed upregulation of Akt-endothelial nitric oxide-nitric oxide-cGMP-GS3Kβ signaling early in the progression of hypertrophy and heart failure.

CONCLUSIONS:

These results support the emerging concept that nitrite therapy may be a viable clinical option for increasing NO levels and may have a practical clinical use in the treatment of heart failure.

KEYWORDS:

cardiomyopathy, hypertrophic; cyclic GMP; heart failure; nitric oxide; nitric oxide synthase; ventricular function, left

PMID:
24599803
PMCID:
PMC4943032
DOI:
10.1161/CIRCRESAHA.114.301475
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center